AbbVie, Caribou Biosciences to Collaborate on CAR-T Cell Products
February 10 2021 - 8:57AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Wednesday said it signed a collaboration and
license agreement with privately held Caribou Biosciences Inc. to
develop new chimeric antigen receptor, or CAR-T, cell
therapies.
The North Chicago, Ill., biopharmaceutical company said it would
use Caribou's CRISPR genome-editing and cell-therapy technologies
to research and develop two new CAR-T cell therapies directed to
targets specified by AbbVie.
AbbVie said Caribou would receive $40 million in an up-front
cash payment and equity investment. Caribou would also be eligible
for up to $300 million in development, regulatory and launch
milestone payments, along with royalties on sales.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 10, 2021 08:42 ET (13:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
